Nuvectis Pharma, Inc. Financials
This page shows Nuvectis Pharma, Inc. (NVCT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Nuvectis Pharma, Inc. passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Nuvectis Pharma, Inc. generates $0.61 in operating cash flow (-$16.0M OCF vs -$26.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Nuvectis Pharma, Inc. reported -$26.4M in net income in fiscal year 2025. This represents a decrease of 39.2% from the prior year.
Nuvectis Pharma, Inc. earned $-1.32 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 18.9% from the prior year.
Cash & Balance Sheet
Nuvectis Pharma, Inc. held $31.6M in cash against $0 in long-term debt as of fiscal year 2025.
Nuvectis Pharma, Inc. paid $0.00 per share in dividends in fiscal year 2025.
Nuvectis Pharma, Inc. had 26M shares outstanding in fiscal year 2025. This represents an increase of 35.9% from the prior year.
Margins & Returns
Nuvectis Pharma, Inc.'s ROE was -143.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 52.0 percentage points from the prior year.
Capital Allocation
Nuvectis Pharma, Inc. invested $18.2M in research and development in fiscal year 2025. This represents an increase of 40.5% from the prior year.
NVCT Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $5.8M+59.8% | $3.6M-1.8% | $3.7M | N/A | $2.8M-4.2% | $2.9M+10.6% | $2.7M |
| SG&A Expenses | N/A | $2.0M-32.3% | $3.0M+57.9% | $1.9M | N/A | $1.5M-9.4% | $1.7M-2.1% | $1.7M |
| Operating Income | N/A | -$7.8M-18.2% | -$6.6M-18.4% | -$5.6M | N/A | -$4.4M+6.1% | -$4.6M-5.6% | -$4.4M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$7.5M-17.8% | -$6.3M-18.8% | -$5.3M | N/A | -$4.2M+6.2% | -$4.4M-6.2% | -$4.2M |
| EPS (Diluted) | N/A | $-0.44-46.7% | $-0.30-11.1% | $-0.27 | N/A | $-0.24+7.7% | $-0.26-4.0% | $-0.25 |
NVCT Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $31.7M-10.9% | $35.6M+31.8% | $27.0M-10.4% | $30.1M+62.0% | $18.6M+7.5% | $17.3M-5.4% | $18.3M-7.2% | $19.7M |
| Current Assets | $31.7M-10.9% | $35.6M+31.8% | $27.0M-10.4% | $30.1M+62.0% | $18.6M+7.5% | $17.3M-5.4% | $18.3M-7.2% | $19.7M |
| Cash & Equivalents | $31.6M-10.7% | $35.4M+32.3% | $26.8M-10.3% | $29.9M+61.1% | $18.5M+7.9% | $17.2M-5.2% | $18.1M-6.9% | $19.5M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $13.3M+14.8% | $11.6M+14.2% | $10.1M+10.2% | $9.2M+3.4% | $8.9M+40.8% | $6.3M+9.5% | $5.8M+1.4% | $5.7M |
| Current Liabilities | $13.3M+14.8% | $11.6M+14.2% | $10.1M+10.2% | $9.2M+3.4% | $8.9M+40.8% | $6.3M+9.5% | $5.8M+1.4% | $5.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $18.4M-23.3% | $24.0M+42.3% | $16.9M-19.5% | $21.0M+115.7% | $9.7M-11.6% | $11.0M-12.3% | $12.5M-10.7% | $14.0M |
| Retained Earnings | -$99.7M-7.9% | -$92.4M-8.8% | -$84.9M-8.1% | -$78.6M-7.3% | -$73.2M-9.3% | -$67.0M-6.6% | -$62.8M-7.6% | -$58.4M |
NVCT Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.0M+11.6% | -$4.5M-33.5% | -$3.4M+19.3% | -$4.2M-69.3% | -$2.5M-2.5% | -$2.4M+20.4% | -$3.0M+30.7% | -$4.4M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | $0 | N/A | N/A | N/A | $0 |
| Financing Cash Flow | $166K-98.7% | $13.1M+4340.2% | $296K-98.1% | $15.5M+304.9% | $3.8M+162.8% | $1.5M-12.9% | $1.7M-64.4% | $4.7M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
NVCT Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | -31.1%+6.5pp | -37.5%-12.1pp | -25.4% | N/A | -37.8%-2.5pp | -35.3%-5.6pp | -29.8% |
| Return on Assets | N/A | -21.0%+2.5pp | -23.4%-5.8pp | -17.7% | N/A | -24.0%+0.2pp | -24.2%-3.0pp | -21.2% |
| Current Ratio | 2.38-0.7 | 3.07+0.4 | 2.66-0.6 | 3.28+1.2 | 2.09-0.6 | 2.74-0.4 | 3.17-0.3 | 3.46 |
| Debt-to-Equity | 0.72+0.2 | 0.48-0.1 | 0.60+0.2 | 0.44-0.5 | 0.92+0.3 | 0.57+0.1 | 0.46+0.1 | 0.41 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Nuvectis Pharma, Inc. profitable?
No, Nuvectis Pharma, Inc. (NVCT) reported a net income of -$26.4M in fiscal year 2025.
What is Nuvectis Pharma, Inc.'s return on equity (ROE)?
Nuvectis Pharma, Inc. (NVCT) has a return on equity of -143.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Nuvectis Pharma, Inc.'s operating cash flow?
Nuvectis Pharma, Inc. (NVCT) generated -$16.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Nuvectis Pharma, Inc.'s total assets?
Nuvectis Pharma, Inc. (NVCT) had $31.7M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Nuvectis Pharma, Inc. spend on research and development?
Nuvectis Pharma, Inc. (NVCT) invested $18.2M in research and development during fiscal year 2025.
What is Nuvectis Pharma, Inc.'s current ratio?
Nuvectis Pharma, Inc. (NVCT) had a current ratio of 2.38 as of fiscal year 2025, which is generally considered healthy.
What is Nuvectis Pharma, Inc.'s debt-to-equity ratio?
Nuvectis Pharma, Inc. (NVCT) had a debt-to-equity ratio of 0.72 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Nuvectis Pharma, Inc.'s return on assets (ROA)?
Nuvectis Pharma, Inc. (NVCT) had a return on assets of -83.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Nuvectis Pharma, Inc.'s cash runway?
Based on fiscal year 2025 data, Nuvectis Pharma, Inc. (NVCT) had $31.6M in cash against an annual operating cash burn of $16.0M. This gives an estimated cash runway of approximately 24 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Nuvectis Pharma, Inc.'s Piotroski F-Score?
Nuvectis Pharma, Inc. (NVCT) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nuvectis Pharma, Inc.'s earnings high quality?
Nuvectis Pharma, Inc. (NVCT) has an earnings quality ratio of 0.61x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.